| Knoop, Karol |
FLUTE-3, NCT05634746: 24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3) |
|
|
| Completed | 3 | 218 | Canada, US | APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy | Ellodi Pharmaceuticals, LP | Eosinophilic Esophagitis | 08/24 | 08/24 | | |
| Adeoti, Adekunle |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
| Mehta, Saumil |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
NCT05171673: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury |
|
|
| Completed | 3 | 151 | US | Licart™ (diclofenac epolamine) topical system, diclofenac epolamine | IBSA Institut Biochimique SA | Soft Tissue Injuries | 06/24 | 07/24 | | |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
| Active, not recruiting | 2 | 87 | US | SAP-001, Xanthine Oxidase Inhibitor, Colchicine | Shanton Pharma Pte. Ltd. | Gout | 01/25 | 02/25 | | |
| Cantisano, Ana |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma |
|
|
| Recruiting | 3 | 292 | US, RoW | FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Asthma | 01/27 | 01/27 | | |
NCT06553547: 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
|
|
| Recruiting | 2 | 72 | US | Tenapanor, IBSRELA, Placebo | Ardelyx | Irritable Bowel Syndrome with Constipation (IBS-C) | 06/26 | 06/26 | | |
| Olvera, Roberto |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
| Recruiting | N/A | 500 | US | EsoGuard, EsoGuard test on cells collected using EsoCheck | Lucid Diagnostics, Inc. | Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma | 09/23 | 09/23 | | |
| Ben-Yair, Vered Katz |
FLUTE-3, NCT05634746: 24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3) |
|
|
| Completed | 3 | 218 | Canada, US | APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy | Ellodi Pharmaceuticals, LP | Eosinophilic Esophagitis | 08/24 | 08/24 | | |
| Ringheanu, Mihaela |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
NCT06553547: 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
|
|
| Recruiting | 2 | 72 | US | Tenapanor, IBSRELA, Placebo | Ardelyx | Irritable Bowel Syndrome with Constipation (IBS-C) | 06/26 | 06/26 | | |
